Related Experiment Video
Updated: Jul 23, 2025
09:44
Author Spotlight: Advancing Cell Therapy Manufacturing with Dissolvable Microcarriers
Published on: July 7, 2023
3.4K
Scale-Up of Academic Mesenchymal Stromal Cell Production
Caroline Laroye1,2, Mélanie Gauthier1,2, Jessica Morello1
1CHRU Nancy, Cell Therapy and Tissue Bank Unit, MTInov Bioproduction and Biotherapy Integrator, F-54000 Nancy, France.
Journal of Clinical Medicine
|July 14, 2023
Summary
Intermediate cryopreservation of mesenchymal stromal cells (MSCs) boosts production yields for severe SARS-CoV-2 infection treatments. This method shows minimal impact on MSC identity, safety, and functionality, ensuring therapeutic potential.
Area of Science:
- Cellular Biology
- Regenerative Medicine
- Immunology
Background:
- Mesenchymal stromal cells (MSCs) are investigated for severe SARS-CoV-2 infection.
- Rapid MSC production was necessary during the COVID-19 pandemic.
- Production methods, including cryopreservation, can affect MSC properties.
Purpose of the Study:
- To evaluate the impact of intermediate cryopreservation on MSC production yields.
- To assess the effects of this process on MSC identity, safety, and functionality.
Main Methods:
- Compared WJ-MSC batches with single vs. intermediate cryopreservation.
- Assessed identity (phenotype, clonogenic capacity), safety (karyotype, sterility), and functionality (viability, mixed lymphocyte reaction).
- All processes followed good manufacturing practices.
Main Results:
- No significant differences were found between production processes.
- Clonogenic capacity was decreased but remained within specifications.
- Production yield increased with intermediate cryopreservation.
Conclusions:
- Intermediate cryopreservation increases MSC production yield.
- This method has minimal impact on essential MSC characteristics.
- This approach supports efficient MSC generation for clinical applications.
